CompletedPhase 4NCT00670007

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
CSL Behring
Principal Investigator
Program Director, Clinical R&D
CSL Behring
Intervention
Alpha1- proteinase inhibitor [human](biological)
Enrollment
140 enrolled
Eligibility
18 years · All sexes
Timeline
20082014

Study locations (21)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00670007 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency

← Back to all trials